ILDONG HOLDINGS CO.,LTD
Financials
Valuation Metrics
ILDONG HOLDINGS CO.,LTD's Market Cap is ₩651B. At end of 2025 it was ₩1534B. Ranked #1524 of 2,410 in KR market (top 63%), #637 of 779 on KOSPI (top 82%), #167 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 72%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 65.09B KRW | KR#1,524/2,410 Sec#167/231 |
| Revenue | 595.15B KRW | KR#561/2,410 Sec#26/231 |
| Net Income | 43.94B KRW | KR#460/2,410 Sec#28/231 |
| Total Assets | 802.86B KRW | KR#550/2,410 Sec#30/231 |
| Net Assets | 345.58B KRW | KR#663/2,410 Sec#42/231 |
| Employees | 84 | KR#1,775/2,410 Sec#145/231 |
| Value | ||
| P/E | 1.48x | KR#47/2,410 Sec#2/231 |
| P/B | 0.19x | KR#136/2,410 Sec#4/231 |
| P/S | 0.11x | KR#186/2,410 Sec#1/231 |
| EV/EBITDA | 8.45x | KR#563/2,410 Sec#24/231 |
| FCF Yield | 19.71% | KR#363/2,410 Sec#6/231 |
| Profitability | ||
| ROE | 12.72% | KR#429/2,410 Sec#30/231 |
| ROA | 5.47% | KR#682/2,410 Sec#57/231 |
| Op. Margin | 3.97% | KR#1,093/2,410 Sec#77/231 |
| Revenue Growth | -5.76% | KR#1,800/2,410 Sec#171/231 |
| Earnings Growth | -34.80% | KR#1,002/2,410 Sec#65/231 |
| Financial Health | ||
| Debt Ratio | 132.32% | KR#1,805/2,410 Sec#201/231 |
| Total Debt | 211.25B KRW | KR#499/2,410 Sec#24/231 |
| FCF | 12.83B KRW | KR#643/2,410 Sec#36/231 |
| Cash | 76.61B KRW | KR#571/2,410 Sec#28/231 |
| Current Ratio | 0.81x | KR#1,924/2,410 Sec#188/231 |
| Net Debt/EBITDA | 5.70x | KR#1,069/2,410 Sec#80/231 |
| Dividend | ||
| Div. Yield | 1.76% | KR#984/2,410 Sec#51/231 |
| Div. Growth | -94.67% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -33.41% | KR#1,517/2,410 Sec#123/231 |
| 1M Return | -8.89% | KR#728/2,410 Sec#77/231 |
| From 52W High | -67.15% | KR#1,949/2,410 Sec#165/231 |
| 1Y MDD | -64.90% | KR#1,706/2,410 Sec#143/231 |
| Trading | ||
| Volume | 9,647 shares | KR#1,707/2,410 Sec#176/231 |
| Trading Value | 54.3M KRW | KR#1,568/2,410 Sec#164/231 |
| Foreign Own. | 2.50% | KR#1,454/2,410 Sec#138/231 |
| Per Share | ||
| EPS | 3,808 KRW | KR#282/2,410 Sec#18/231 |
| BPS | 29,945 KRW | KR#380/2,410 Sec#28/231 |
Company Info
Established in 1941, this company transitioned to a holding company structure in 2016, with Ildong Pharmaceutical and UNIQPLAN as its main subsidiaries. Its subsidiaries engage in diverse businesses such as pharmaceutical manufacturing and sales, advertising agency services, and software development, generating profits through investments and other activities. The company is strengthening its competitiveness by establishing a fast and professional decision-making system and pursuing the dispersion of management risks by concentrating corporate capabilities. Ildong Holdings was founded in 1941 and is headquartered in Seocho-gu, Seoul.